The European Patent Office (EPO) has granted patent EP3609956B1 for a novel hydrogel composition designed for cell culture and various biomedical applications. The patent, effective March 18, 2026, details specific International Patent Classifications (IPCs) including A61L (Medical and veterinary science; hygiene) and C12N (Micro-organisms or enzymes; compositions thereof).

This grant signifies the formal recognition of intellectual property rights for this technology within the designated European states. While not a regulatory rule imposing obligations on companies, it impacts the competitive landscape for entities involved in biotechnology, cell culture, and the development of biomedical products. Companies operating in these sectors should be aware of this granted patent when developing new products or research strategies.